tiprankstipranks
Trending News
More News >
Protalix Biotherapeutics (PLX)
:PLX
Advertisement

Protalix (PLX) AI Stock Analysis

Compare
845 Followers

Top Page

PLX

Protalix

(NYSE MKT:PLX)

Rating:62Neutral
Price Target:
$1.50
▼(-3.23%Downside)
Protalix's overall stock score reflects significant improvements in financial health and promising developments in its clinical pipeline. However, inconsistent revenue growth and high leverage are risks. The technical indicators suggest weak momentum, and valuation appears high, which could limit upside potential. The recent leadership change is expected to positively impact future growth strategies.
Positive Factors
Commercial Approval
Elfabrio remains favorable with commercial approval across 23 territories globally for the treatment of Fabry disease.
Financial Health
The company has $34.7M in cash and short-term bank deposits, expected to be sufficient to fund operations to cash flow breakeven.
Negative Factors
Revenue Performance
Protalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.
Royalty-Based Revenue
Protalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.

Protalix (PLX) vs. SPDR S&P 500 ETF (SPY)

Protalix Business Overview & Revenue Model

Company DescriptionProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
How the Company Makes MoneyProtalix generates revenue through the development and commercialization of its proprietary products and by licensing its technology to other pharmaceutical companies. A significant portion of its income comes from product sales, particularly its FDA-approved treatments. The company also earns revenue through milestone payments and royalties from strategic partnerships and collaborations with other pharmaceutical firms, leveraging its ProCellEx platform to develop new therapeutic proteins. These partnerships help expand its market reach and contribute to its earnings by sharing the costs and potential profits of drug development.

Protalix Earnings Call Summary

Earnings Call Date:May 09, 2025
(Q1-2025)
|
% Change Since: -46.37%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive and negative aspects. The company showcased substantial revenue growth, promising developments in its pipeline, and a strong cash position. However, these were counterbalanced by increased costs associated with goods sold and R&D, alongside a continued net loss. The sentiment of the call is balanced.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
Revenues from selling goods increased by 70% to $10 million in Q1 2025 compared to $3.7 million in Q1 2024. This was primarily driven by a $5.9 million increase in sales to Pfizer and a $400,000 increase in sales to Fircruz in Brazil.
Positive Developments for PRX-115
Encouraging results from the first in human study of PRX-115, showing increased exposure and a rapid reduction in plasma uric acid levels in a dose-dependent manner. Plans to initiate a phase two clinical trial for PRX-115 in gout patients later this year.
Reduction in Operating Expenses
Selling, general, and administrative expenses decreased by 16% to $2 million in Q1 2025 from $3.1 million in Q1 2024, primarily due to a decrease in salary-related expenses and selling expenses.
Cash Position
Cash, cash equivalents, and short-term bank deposits were approximately $34.7 billion as of March 31, 2025.
Negative Updates
Increased Cost of Goods Sold
Cost of goods sold increased by 215% to $8.2 million in Q1 2025 from $2.6 million in Q1 2024, primarily due to increased sales to Pfizer and Fircruz in Brazil.
Higher Research and Development Expenses
Total research and development expenses increased by 21% to approximately $3.5 million in Q1 2025 from $2.9 million in Q1 2024, driven primarily by the advancement in the clinical pipeline.
Net Loss
Net loss for Q1 2025 was approximately $3.6 million or $0.05 per share, compared to $4.6 million or $0.06 per share in Q1 2024.
Company Guidance
During the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call, the company reported a 70% increase in revenues from selling goods, reaching $10 million for the quarter ending March 31, 2025, compared to $3.7 million in the same period the previous year. This increase was driven primarily by a $5.9 million uptick in sales to Pfizer and an additional $400,000 in sales to Fircruz in Brazil. Despite the revenue growth, the cost of goods sold also rose by 215% to $8.2 million. Research and development expenses increased by 21% to $3.5 million, reflecting ongoing advancements in their clinical pipeline. The company also highlighted their cash position, with cash, cash equivalents, and short-term bank deposits totaling approximately $34.7 billion as of March 31, 2025. Looking forward, Protalix BioTherapeutics aims to initiate a phase two clinical trial for PRX-115 later in the year and is working closely with Chiesi Global Rare Diseases on the potential approval of a reduced dosing frequency for their Fabry disease treatment by the European Medicines Agency.

Protalix Financial Statement Overview

Summary
Protalix has shown significant improvement in profitability and cash flow, which are crucial for financial stability. While leverage remains a concern due to a high debt-to-equity ratio, the overall trend suggests positive momentum in financial health. Continued focus on revenue growth and debt reduction will be vital.
Income Statement
65
Positive
The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.
Balance Sheet
55
Neutral
Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.
Cash Flow
70
Positive
The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue53.40M65.49M47.64M38.35M62.90M
Gross Profit29.08M42.51M28.05M22.00M52.02M
EBITDA6.52M12.94M-10.78M-18.94M4.45M
Net Income2.93M8.31M-14.93M-27.58M-6.52M
Balance Sheet
Total Assets73.42M84.43M55.79M73.67M67.93M
Cash, Cash Equivalents and Short-Term Investments34.83M44.56M22.18M38.98M38.55M
Total Debt5.53M26.28M33.47M33.47M64.40M
Total Liabilities30.21M50.87M66.43M79.70M94.97M
Stockholders Equity43.21M33.57M-10.64M-6.04M-27.04M
Cash Flow
Free Cash Flow7.39M-2.47M-25.63M-11.74M-26.76M
Operating Cash Flow8.67M-1.32M-25.00M-10.29M-26.11M
Investing Cash Flow4.22M-16.71M-5.04M18.92M-19.95M
Financing Cash Flow-16.79M24.67M8.24M12.08M46.47M

Protalix Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.55
Price Trends
50DMA
1.53
Positive
100DMA
2.03
Negative
200DMA
1.91
Negative
Market Momentum
MACD
-0.02
Negative
RSI
55.72
Neutral
STOCH
82.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Neutral. The current price of 1.55 is above the 20-day moving average (MA) of 1.48, above the 50-day MA of 1.53, and below the 200-day MA of 1.91, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 55.72 is Neutral, neither overbought nor oversold. The STOCH value of 82.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLX.

Protalix Risk Analysis

Protalix disclosed 64 risk factors in its most recent earnings report. Protalix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Protalix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$123.39M36.9010.42%0.18%-55.15%
59
Neutral
$439.45M-86.09%1250.63%37.24%
54
Neutral
$266.86M-198.47%-38.86%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
45
Neutral
$531.89M-32.12%10.98%
36
Underperform
$132.20M-244.16%77.12%
35
Underperform
$425.06M-500.57%81.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PLX
Protalix
1.55
0.40
34.78%
LXRX
Lexicon Pharmaceuticals
1.13
-1.20
-51.50%
DBVT
DBV Technologies SA - American
9.78
4.63
89.90%
HURA
TuHURA Biosciences
2.84
-4.76
-62.63%
GOSS
Gossamer Bio
1.78
0.69
63.30%
TERN
Terns Pharmaceuticals
6.06
-2.73
-31.06%

Protalix Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Protalix Appoints New CFO to Boost Growth Strategy
Positive
Jul 21, 2025

On July 21, 2025, Protalix BioTherapeutics announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. Mamlok, with three decades of experience in healthcare and technology sectors, is expected to play a crucial role in executing Protalix’s growth strategy. The transition is designed to be seamless with Rubin assisting until October 2025. This leadership change is anticipated to strengthen Protalix’s financial and operational strategies, further solidifying its position in the biopharmaceutical industry.

The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Protalix Holds Annual Stockholders Meeting in Tel Aviv
Neutral
Jun 26, 2025

On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025